- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06150989
Black Women's Life Experience On Cardiovascular Health Via Ongoing Monitoring (BLOOM)
A Biobehavioral Approach to Understand the Multilevel Determinants of Cardiovascular Health in Black Women
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Texas
-
Arlington, Texas, United States, 76010
- The University of Texas at Arlington
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- born and identified as female;
- between 18-49 years old;
- self-identify as Black or African American;
- not currently pregnant;
- ownership of a smartphone with Internet access;
- able to speak and read English
Exclusion Criteria:
- diagnosed hypertension, cardiovascular, respiratory, metabolic, and/or neurological disorders;
- functional limitations or health issues that preclude physical activity;
- currently taking medications for thyroid function or psychological conditions such as depression, anxiety, and mood disorders;
- current use of oral or inhalant corticosteroids for asthma;
- have regularly smoked within the last 2 years.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational Group
Black women enrolled in this study will complete a series of lab-based assessments that evaluate their vascular health, followed by a 10-day free-living monitoring period with mobile and wearable devices.
|
All participants will go through a series of lab-based assessments to evaluate their vascular health. These assessments include: heart rhythm/rate, blood pressure, large blood vessel flow, central aortic blood pressure and pulse wave velocity, brain blood flow, carbon dioxide concentration, flow mediated dilation/blood vessel responsiveness, breathing rate, and cerebral vasomotor reactivity. In addition, venous blood sample will be taken to identify biomarkers that are associated with elevating blood pressure and decreasing blood flow. The 10-day monitoring period includes a wrist-worn activity tracker and a blood pressure monitor bracelet; a smartphone app that will prompt surveys up to 6 times a day to assess behaviors, social/physical context, mood/stress, and experience of racial discrimination/microaggression. Participants will also collect saliva samples on three consecutive days during the 10-day monitoring period. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Macrovascular function
Time Frame: Day 1
|
Macrovascular function will be assessed as brachial artery vasodilation following a period of suprasystolic cuff occlusion.
Microvascular function will be assessed as the % change in blood velocity from baseline following cuff release.
|
Day 1
|
|
Arterial Stiffness
Time Frame: Day 1
|
An appropriately sized blood pressure cuff will be placed on the upper arm and central (aortic) and peripheral (arm) blood pressure will be assessed using the non-invasive SphygmoCor Xcel device.
This device provides measurement of augmentation index (in percentage), which is an indicator of arterial stiffness.
|
Day 1
|
|
Blood Flow Measurements (Large Blood Vessels)
Time Frame: Day 1
|
A Doppler ultrasound probe will be used to measure blood flow in the upper arm, leg, and/or neck (e.g., brachial artery, femoral artery, and carotid artery, respectively).
|
Day 1
|
|
Blood Flow Measurements (Cerebral Blood Vessels)
Time Frame: Day 1
|
Cerebral blood flow will be indexed from the velocity of blood flowing through the middle cerebral artery.
This will be accomplished using transcranial Doppler ultrasound.
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical activity
Time Frame: Day 2 to Day 11
|
Daily physical activity level will be assessed via a wrist-worn accelerometer.
|
Day 2 to Day 11
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-0344
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.